Retatrutide is currently an investigational triple-hormone receptor agonist being developed by Eli Lilly and Company targeting GLP-1 GIP and glucagon receptors to drive significant weight loss and metabolic improvement Clinical trials known as the SURMOUNT program are ongoing globally including trial sites across the United Kingdom to evaluate its efficacy and safety profile Consequently the […]